EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Adipocyte‐Derived Palmitic Acid Promotes Breast Cancer Malignancy via ZDHHC15 ‐Mediated S‐Palmitoylation of PPARγ

Geon Ho Moon, Min Young Lee, Jiwon Koh, Ki Yong Hong, Junji Fukuda, Sung Joon Kim, Yang-Sook Chun iD

Cancer Science · 2026-11 · 117 (11) · 3007-3021

DOI: 10.1111/cas.70487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 30.07.2026. Verfasst von Geon Ho Moon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: PPAR gamma, Breast Neoplasms, Palmitic Acid, Adipocytes. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peroxisome proliferator‐activated receptor gamma (PPARγ), a well‐characterized regulator of adipogenesis, also functions as a tumor suppressor in breast cancer. However, the PPARγ agonist rosiglitazone has shown limited clinical efficacy, highlighting the importance of understanding PPARγ regulation within the tumor microenvironment. Here, we demonstrate that adipocyte‐derived palmitic acid promotes PPARγ S‐palmitoylation via zinc finger DHHC‐domain containing protein 15 (ZDHHC15), as confirmed by acyl‐biotin exchange (ABE) assay. Immunoblot, RT‐qPCR, and immunoprecipitation further revealed that this modification leads to ubiquitin‐mediated proteasomal degradation of PPARγ. Functional studies using adipocyte‐conditioned media and an oxygen‐permeable 3D spheroid culture system showed that PPARγ palmitoylation promotes breast cancer malignancy and confers resistance to rosiglitazone. Notably, the palmitoylation inhibitor 2‐bromopalmitate (2‐BP) stabilizes PPARγ, suppressing breast cancer malignancy. Furthermore, 2‐BP synergistically enhances the therapeutic efficacy of rosiglitazone, suggesting that targeting PPARγ S‐palmitoylation represents a promising therapeutic strategy in breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PPAR gammaBreast NeoplasmsPalmitic AcidAdipocytesAcyltransferasesFemaleHumansLipoylationRosiglitazoneAnimalsPPAR-gamma AgonistsCell Line, TumorPalmitatesMice

Stichwörter der Autor:innen

PPARγZDHHC15adipocytesbreast cancerpalmitoylation

Substanzen

PPAR gammaPalmitic AcidRosiglitazone2-bromopalmitatePPAR-gamma AgonistsAcyltransferasesPalmitates

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Physiology, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.
  • Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
  • Department of Plastic and Reconstructive Surgery, Seoul National University Hospital, Seoul, Republic of Korea.
  • Faculty of Engineering, Yokohama National University, Yokohama, Japan.

ORCID-Profile: Yang-Sook Chun

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Moon, G. H., Lee, M. Y., Koh, J., Hong, K. Y., Fukuda, J., Kim, S. J., & Chun, Y. S. (2026). Adipocyte‐Derived Palmitic Acid Promotes Breast Cancer Malignancy via ZDHHC15 ‐Mediated S‐Palmitoylation of PPARγ. Cancer Science, 117(11), 3007-3021. https://doi.org/10.1111/cas.70487

Vancouver

Moon GH, Lee MY, Koh J, Hong KY, Fukuda J, Kim SJ, et al. Adipocyte‐Derived Palmitic Acid Promotes Breast Cancer Malignancy via ZDHHC15 ‐Mediated S‐Palmitoylation of PPARγ. Cancer Science. 2026;117(11):3007-3021. doi:10.1111/cas.70487

BibTeX
@article{Moon2026,
  author = {Moon, Geon Ho and Lee, Min Young and Koh, Jiwon and Hong, Ki Yong and Fukuda, Junji and Kim, Sung Joon and Chun, Yang-Sook},
  title = {Adipocyte‐Derived Palmitic Acid Promotes Breast Cancer Malignancy via ZDHHC15 ‐Mediated S‐Palmitoylation of PPARγ},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {11},
  pages = {3007--3021},
  doi = {10.1111/cas.70487}
}
Kostenlos starten →